Ultrahigh-energy photons up to 1.4 petaelectronvolts from 12 γ-ray Galactic sources

Cao, Z.; Aharonian, F.; An, Qi; Axikegu,; Bai, Lixin; Bai, Y.; Bao, Yiwei; Bastieri, D.; Bi, X. J.; Bi, Y. J.; Cai, H.; Cai, J. T.; Cao, Zhe; Chang, Jin; Chang, X. C.; Chen, B M; Chen, J; Chen, L; Chen, Liang; Chen, Long; Chen, M J; Chen, Q H; Chen, S H; Chen, T L; Chen, X L; Chen, Y; Cheng, Ning; Cheng, Yaodong; Cui, S. W.; Cui, Xiaohong; Cui, Yudong; Dai, B. Z.; Dai, H. L.; Dai, Z. G.; Danzengluobu,; Volpe, D. della; Piazzoli, B. D’Ettorre; Dong, X.; Fan, J. H.; Fan, Yi‐Zhong; Zhou, Fan; Fang, Jun; Fang, Kun; Feng, C.; Liu, Feng; Feng, S. H.; Feng, Y. L.; Gao, Bo; Gao, Chengyong; Gao, Qi; Gao, Wei; Ge, M. M.; Geng, L. S.; Gong, Guanghua; Gou, Q. B.; Gu, M. H.; Guo, J. G.; Guo, Xiaolei; Guo, Y. Q.; Guo, Yaoyao; Han, Y. A.; He, H. H.; He, J.; He, S. L.; He, Xinbo; He, Y.; Heller, M.; Hor, Y. K.; Hou, Chao; Hou, X.; Hu, Hongbo; Hu, S. C.; Hu, X.; Huang, D.; Huang, Q.; Huang, Wenhao; Huang, X. T.; Huang, Z. C.; Ji, Fei; Ji, X. L.; Jia, H. Y.; Jiang, K.; Jiang, Ze-Jun; Jin, C.; Kuleshov, D.; Levochkin, K.; Li, B B; Li, Cong; Li, Cheng; Li, F; Li, H B; Li, J; Li, K; Li, W L; Li, X; Li, Xin; Li, X R; Li, Y; Li, Y Z; Li, Zhe; Li, Zhuo; Liang, En‐Wei; Liang, Yun-Feng; Lin, S. J.; Liu, B; Liu, C; Liu, D; Liu, H; Liu, H D; Liu, J; Liu, J L; Liu, J S; Liu, M Y; Liu, R Y; Liu, S M; Liu, W; Liu, Y N; Liu, Z X; Long, W. J.; Lü, Rui; Lv, Hongkui; Q, B; L, L; H, X; Mao, J.; Masood, A.; Mitthumsiri, W.; Montaruli, T.; Nan, Y. C.; Pang, B. Y.; Pattarakijwanich, P.; Pei, Z. Y.; Qi, M. Y.; Ruffolo, D.; Rulev, V.; Sáiz, A.; Shao, L.; Shchegolev, O. B.; Sheng, X. D.; Shi, Jingyan; Song, H. C.; Stenkin, Yu. V.; Stepanov, V.; Sun, Q. N.; Sun, Xiao-Na; Sun, Zhenyu; Tam, P. H. T.; Tang, Z.; Tian, Wei; Wang, B D; Wang, C; Wang, H; Wang, H G; Wang, J C; Wang, J S; Wang, L P; Wang, L Y; Wang, R N; Wang, W; Wang, X G; Wang, X J; Wang, X Y; Wang, Y D; Wang, Zheng; Wang, Zhen; Wang, Z H; Wang, Z X; Wei, Da-Ming; Wei, Jianyan; Wei, Y. J.; Wen, Tao; Wu, C. Y.; Wu, H. R.; Wu, San; Wu, W. X.; Wu, Xiang-Ping; Xi, Shao-Qiang; Xia, J.; Xiang, G. M.; Xiao, G. C.; Xiao, H. B.; Xin, G. G.; Xin, Y.; Xing, Yongzhong; Xu, D. L.; Xu, R. X.; Xue, L.; Yan, Dahai; Yang, Chaowen; Yang, Fang; Yang, Jian-Huan; Yang, Lili; Yang, Min; Yang, R.; Yang, S. B.; Yao, Y. H.; Yao, Z. G.; Ye, Y M; Yin, L. Q.; Yin, Na; You, X. H.; You, Z. Y.; Yu, Y. H.; Yuan, Qiang; Zeng, Houdun; Zeng, Tingxuan; Zeng, W.; Zeng, Z. K.; Zha, M.; Zhai, X. X.; Zhang, B B; Zhang, H M; Zhang, H Y; Zhang, J L; Zhang, J W; Zhang, L; Zhang, Li; Zhang, L X; Zhang, P F; Zhang, P P; Zhang, R; Zhang, S R; Zhang, S S; Zhang, X; Zhang, X P; Zhang, Yong; Zhang, Yi; Zhang, Y F; Zhang, Y L; Zhao, Bing; Zhao, Jing; Liu, Zhao; Zhao, S. P.; Zheng, F.; Zheng, Y.; Zhou, Bin; Zhou, H.; Zhou, Jing-Zhi; Zhou, Ping; Zhou, Rong; Zhou, X. X.; Zhu, C. G.; Zhu, F. R.; Zhu, Hui; Zhu, K.; Zuo, Xin

doi:10.1038/s41586-021-03498-z

Cited by 358 publications

(332 citation statements)

References 50 publications

Supporting

Mentioning

320

Contrasting

Unclassified

Order By: Relevance

“…In addition to being an antimycobacterial agent, clofazimine also possesses anti-inflammatory properties primarily by inhibiting T lymphocyte activation and proliferation 39 . Yuan et al found that clofazimine inhibits SARS-CoV-2 replication by interfering with spike-mediated viral entry and viral RNA replication 40 . Their work also demonstrated that clofazimine has antiviral efficacy against SARS-CoV-2 in human embryonic stem cell-derived cardiomyocytes and in an ex vivo human lung culture system, as well as antiviral synergy with remdesivir demonstrating the potential of clofazimine as part of a combination treatment regimen for COVID-19 40 .…”

Section: Discussionmentioning

confidence: 99%

Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19

Andreoletti

Oskotsky

et al. 2021

Sci Rep

View full text Add to dashboard Cite

The novel SARS-CoV-2 virus emerged in December 2019 and has few effective treatments. We applied a computational drug repositioning pipeline to SARS-CoV-2 differential gene expression signatures derived from publicly available data. We utilized three independent published studies to acquire or generate lists of differentially expressed genes between control and SARS-CoV-2-infected samples. Using a rank-based pattern matching strategy based on the Kolmogorov–Smirnov Statistic, the signatures were queried against drug profiles from Connectivity Map (CMap). We validated 16 of our top predicted hits in live SARS-CoV-2 antiviral assays in either Calu-3 or 293T-ACE2 cells. Validation experiments in human cell lines showed that 11 of the 16 compounds tested to date (including clofazimine, haloperidol and others) had measurable antiviral activity against SARS-CoV-2. These initial results are encouraging as we continue to work towards a further analysis of these predicted drugs as potential therapeutics for the treatment of COVID-19.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19

Andreoletti

Oskotsky

et al. 2021

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The statistical significance of the gammaray signal from Crab Nebula is 28.0 ϭ at 25-100 TeV and 14.7 ϭ at >100 TeV [5]. As well, the LHAASO collaboration reported about the detection of more than 530 photons at energies above 100 TeV and up to 1.4 PeV from 12 ultrahigh-energy γ-ray sources with a statistical significance greater than 7 ϭ [6].…”

Section: Introductionmentioning

confidence: 87%

TAIGA - an advanced hybrid detector complex for astroparticle physics, cosmic ray physics and gamma-ray astronomy

Буднев¹,

Kuzmichev²,

Mirzoyan³

et al. 2021

Proceedings of 37th International Cosmic Ray Conference — PoS(ICRC2021)

View full text Add to dashboard Cite

show abstract

“…The recent results obtained by the LHAASO Collaboration with half detector in data taking revealed the existence of a large number of gamma-ray sources emitting photons with energies well beyond 500 TeV [1]. The unexpected observation of these sources in the Northern hemisphere suggests the opportunity to discover tens of similar Ultra High Energy emissions in the Inner Galaxy by a detector able to detect PeV photons located in the Southern hemisphere.…”

Section: Introductionmentioning

confidence: 99%

STACEX: RPC-based detector for a multi-messenger observatory in the Southern Hemisphere

Fernandez¹,

Bigongiari²,

Bulgarelli³

et al. 2021

Proceedings of 37th International Cosmic Ray Conference — PoS(ICRC2021)

View full text Add to dashboard Cite

Recent findings by the LHAASO experiment are opening a new window, that of the PeV sky, to the observation of the electromagnetic spectrum. Several astronomical objects emitting gamma-rays at energies well above 100 TeV have been observed with the LHAASO-KM2 array of scintillators and muon detectors, clearly demonstrating the feasibility of gamma-ray astronomy up to PeV energies. An all-sky gamma-ray detector in the Southern Hemisphere, operating in the GeV-PeV range, could complement LHAASO observations, monitor the Inner Galaxy and the Galactic Center looking for PeVatrons. As shown by LHAASO, a water-Cherenkov based detector is not well suited to measure the energy spectrum up to the PeV range, nor to reach the advisable 100 GeV threshold. The ARGO-YBJ experiment, operated for many years at 4300 m a.s.l. with an energy threshold of about 300 GeV, demonstrated, on the contrary, the capability of a carpet of Resistive Plate Chambers (RPCs) to fully reconstruct showers starting from the GeV range up to about 10 PeV. In this contribution we propose a hybrid detector made of a layer of RPCs on top of a water Cherenkov facility devoted to the detection of muons for the selection of gamma-induced showers by the muon-poor technique. We present the layout and discuss the expected performance.

show abstract

Ultrahigh-energy photons up to 1.4 petaelectronvolts from 12 γ-ray Galactic sources

Cited by 358 publications

References 50 publications

Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19

Transcriptomics-based drug repositioning pipeline identifies therapeutic candidates for COVID-19

TAIGA - an advanced hybrid detector complex for astroparticle physics, cosmic ray physics and gamma-ray astronomy

STACEX: RPC-based detector for a multi-messenger observatory in the Southern Hemisphere

Contact Info

Product

Resources

About